MiCardia Corporation

MiCardia Corporation, established in 2004 and based in Irvine, California, is a privately-held medical device company focused on treatments for structural heart disease. The company operates within the surgical devices industry, specifically developing solutions for mitral and tricuspid valve disorders.

The core of MiCardia's business revolves around its proprietary Dynaplasty technology, which is designed to allow for the adjustment of cardiac implants both during and after a surgical procedure. This technology is embodied in its enCor Mitral Valve Repair System, which received CE Mark approval in 2011, permitting its commercialization in the European Union. The system includes the enCorSQ, an annuloplasty device for treating mitral regurgitation (MR), a condition where the heart's mitral valve fails to close properly. A key feature of the enCorSQ is its ability to be adjusted post-implantation in a minimally invasive manner, addressing recurrent regurgitation that can happen as a patient's underlying cardiovascular disease progresses, thereby potentially avoiding repeat open-heart surgeries.

MiCardia's business model centers on the development and sale of these specialized medical devices to healthcare institutions. The company has engaged in multiple funding rounds to support its operations and product commercialization, raising a total of over $33 million. A significant milestone occurred in 2012 when MiCardia spun off its transcatheter technology business into a new entity, ValCar Inc., backed by an $8 million investment to further develop catheter-based, non-surgical implantation methods. The company continues to hold patents for its adjustable implant technologies.

Keywords: medical devices, structural heart disease, mitral valve repair, tricuspid valve repair, Dynaplasty technology, annuloplasty device, cardiac surgery, interventional cardiology, enCor Mitral Valve Repair System, mitral regurgitation treatment, adjustable cardiac implants, minimally invasive surgery, post-operative adjustment, cardiac technology, heart valve disorder, cardiovascular devices, CE Mark, surgical devices, ValCar Inc., cardiac implants